Drug recall · September 13, 2017
Famotidine for Oral Suspension USP recall
Why: CGMP Deviations
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01
- Lots / codes
Lot #: G606950, Exp 07/18
- Quantity
- 12,888 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide in the USA
- Initiated
- May 2, 2017 · Voluntary: Firm initiated
- Classified
- September 1, 2017
- Reported
- September 13, 2017
- Ended
- March 28, 2018
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Famotidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.